Viridian (VRDN) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
302.0K
Operating Income
-299.0M
-99,018.21%
Net Income
-269.9M
-89,387.09%
EPS (Diluted)
-$3.07
Balance Sheet Metrics
Total Assets
742.4M
Total Liabilities
70.8M
Shareholders Equity
671.6M
Debt to Equity
0.11
Cash Flow Metrics
Operating Cash Flow
-227.0M
Free Cash Flow
-232.8M
Revenue & Profitability Trend
Viridian Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 302.0K | 314.0K | 1.8M | 3.0M | 1.0M |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | 299.3M | 254.8M | 136.1M | 82.7M | 41.6M |
| Operating Income | -299.0M | -254.4M | -134.3M | -79.7M | -40.5M |
| Pre-tax Income | -269.9M | -237.7M | -129.9M | -79.4M | -110.7M |
| Income Tax | - | - | - | - | - |
| Net Income | -269.9M | -237.7M | -129.9M | -79.4M | -110.7M |
| EPS (Diluted) | -$3.07 | -$5.31 | -$4.05 | -$6.66 | -$31.13 |
Income Statement Trend
Viridian Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 738.5M | 486.5M | 431.2M | 200.2M | 129.6M |
| Non-Current Assets | 3.9M | 3.9M | 3.9M | 3.5M | 1.6M |
| Total Assets | 742.4M | 490.4M | 435.1M | 203.7M | 131.3M |
| Liabilities | |||||
| Current Liabilities | 47.9M | 26.6M | 33.3M | 13.6M | 10.7M |
| Non-Current Liabilities | 22.9M | 21.8M | 6.7M | 2.4M | 544.0K |
| Total Liabilities | 70.8M | 48.4M | 40.0M | 16.0M | 11.2M |
| Equity | |||||
| Total Shareholders Equity | 671.6M | 442.0M | 395.1M | 187.7M | 120.0M |
Balance Sheet Composition
Viridian Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -269.9M | -237.7M | -129.9M | -79.4M | -110.7M |
| Operating Cash Flow | -227.0M | -175.8M | -98.0M | -55.5M | -34.7M |
| Investing Activities | |||||
| Capital Expenditures | -511.0K | -898.0K | -797.0K | -259.0K | -42.0K |
| Investing Cash Flow | -228.7M | -94.3M | -115.1M | -74.3M | -50.5M |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | 451.7M | 203.9M | 318.4M | 122.9M | 101.3M |
| Free Cash Flow | -232.8M | -185.1M | -94.6M | -54.9M | -29.8M |
Cash Flow Trend
Viridian Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-4.78
Forward P/E
-3.51
Price to Book
2.88
Price to Sales
3,960.72
PEG Ratio
-3.51
Profitability Ratios
Profit Margin
0.00%
Operating Margin
-130,369.45%
Return on Equity
-51.95%
Return on Assets
-32.62%
Financial Health
Current Ratio
19.49
Debt to Equity
3.82
Beta
0.46
Per Share Data
EPS (TTM)
-$3.35
Book Value per Share
$5.09
Revenue per Share
$0.00
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| vrdn | 1.2B | -4.78 | 2.88 | -51.95% | 0.00% | 3.82 |
| Vertex | 114.1B | 32.82 | 6.92 | -5.64% | -8.91% | 10.00 |
| Regeneron | 55.3B | 13.02 | 1.84 | 15.96% | 31.94% | 9.20 |
| Vera Therapeutics | 1.4B | -8.41 | 2.58 | -39.49% | 0.00% | 10.18 |
| Immunocore Holdings | 1.6B | -31.41 | 4.13 | -5.86% | -6.48% | 114.67 |
| Agios | 1.9B | 2.89 | 1.32 | 60.26% | 1,798.26% | 3.61 |
Financial data is updated regularly. All figures are in the company's reporting currency.